ArticleMemorias do Instituto Oswaldo Cruz2026
Analysis of the therapeutic gap for Trypanosoma cruzi infection in Colombia (2012 - 2022).
Article in Memorias do Instituto Oswaldo Cruz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2017, an estimated 1.2% of the population at risk for Chagas disease (CD) in Colombia was screened, and only 0.4% were treated. The recent implementation of CD-related Care roadmap has improved access to diagnosis and treatment. However, a therapeutic gap (TG) persists.
objectivesIn this work, we aim to analyse the TG for Trypanosoma cruzi/CD infection in Colombia over the last years.
methodsThis is a descriptive study estimating the TG for T. cruzi/CD infection between 2012 and 2022. TG is defined as the number of people with a confirmed infection who have the indication of treatment but do not receive it. Two scenarios were considered in the TG analysis: (A) antiparasitic treatment is indicated in 70% of people with confirmed infection; (B) antiparasitic treatment indication in 85%. Data sources were official National and Departmental databases.
findingsIn scenario A, the TG was 77.5% in 2012, and by 2022, decreased to 48.1%. Two phases in the TG dynamics were observed: between 2012 and 2014, there was an increase of 4.5%; from 2014 onwards, there was a reduction of 40.7%. The most important reduction of TG was observed in 2018 and 2019. Linear projections from 2014-2022 indicate a potential reduction to 13.7% by 2030. Nevertheless, there are differences in terms of the reduction observed in different departments. MAIN
conclusionTG calculation allows monitoring of treatment coverage, and its analysis facilitates target interventions to improve it, by reducing TG. Implementing interventions aimed at reducing the TG allows countries like Colombia to take a step forward in CD control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.